Alnylam Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT00496821
- Locations
- 🇺🇸
Alnylam Pharmaceuticals, Cambridge, Massachusetts, United States